Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Pure Bioscience (PURE)

Pure Bioscience (PURE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Pure Bioscience 771 JAMACHA ROAD #512 EL CAJON CA 92019 USA

www.purebio.com P: 619-596-8600

Description:

PURE Bioscience develops and markets technology-based bioscience products that provide solutions to numerous global health challenges, including methicillin-resistant Staphylococcus aureus (MRSA), or staph infection. PURE's proprietary high efficacy/low toxicity bioscience technologies, including its silver dihydrogen citrate-based antimicrobials, represent innovative advances in diverse markets and lead today's global trend toward industry and consumer use of `green` products while providing competitive advantages in efficacy and safety. Patented SDC is an electrolytically generated source of stabilized ionic silver which formulates well with other compounds. As a platform technology, SDC is distinguished from competitors in the marketplace because of its superior efficacy, reduced toxicity and the inability of bacteria to form a resistance to it.

Key Statistics

Overview:

Market Capitalization, $K 7,830
Enterprise Value, $K 7,680
Shares Outstanding, K 111,856
Annual Sales, $ 1,880 K
Annual Net Income, $ -3,960 K
Last Quarter Sales, $ 330 K
Last Quarter Net Income, $ -1,000 K
EBIT, $ -3,260 K
EBITDA, $ -3,140 K
60-Month Beta 0.17
% of Insider Shareholders 41.76%
% of Institutional Shareholders 0.00%
Float, K 65,145
% Float 58.24%
Short Volume Ratio 0.39

Growth:

1-Year Return -50.00%
3-Year Return -89.06%
5-Year Return -84.44%
5-Year Revenue Growth 6.21%
5-Year Earnings Growth 63.64%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.01 on 03/18/24
Latest Earnings Date 06/12/24
Earnings Per Share ttm -0.06
EPS Growth vs. Prev Qtr 0.00%
EPS Growth vs. Prev Year 0.00%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-8 on 08/15/12

PURE Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % 0.00%
Return-on-Assets % -326.30%
Profit Margin % -210.64%
Debt/Equity -1.41
Price/Sales 4.72
Price/Cash Flow N/A
Price/Book N/A
Book Value/Share -0.01
Interest Coverage -395.00
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar